AbbVie 2014 Annual Report Download - page 141

Download and view the complete annual report

Please find page 141 of the 2014 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 182

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182

17MAR201518111135
17MAR201518110996 17MAR201518110855
13NOV201221352027
Total shareholder return (TSR) continued to significantly outperform external indices. Since AbbVie became an
independent company at the beginning of 2013, its TSR is 105.7% through the end of 2014, which places AbbVie at the
top of its Health Care Peer Group, and 52 percentage points above the NYSE Arca Pharmaceuticals Index and
55.2 percentage points above the Standard & Poor’s 500 Index over the same time period. In 2014 alone, AbbVie’s TSR
was 28%, which places AbbVie in the top quartile of its Health Care Peer Group, and 11.4 and 14.3 percentage points
above the NYSE Arca Pharmaceuticals and Standard & Poor’s 500 indices, respectively.
The following graph compares the cumulative total returns of AbbVie, the Standard & Poor’s 500 Index and the
NYSE Arca Pharmaceuticals Index. The graph covers the period from January 2, 2013 (the day AbbVie’s common stock
began ‘‘regular-way’’ trading on the NYSE) through December 31, 2014. The graph assumes $100 was invested in the
stock or the index on January 2, 2013 and also assumes the reinvestment of dividends. The stock price performance in
the following graph is not necessarily indicative of future stock price performance.
Total Shareholder Return Since Separation
$225
$200
$175
$150
$125
$100
1/2/2013 6/30/2013 12/31/2013 6/30/2014 12/31/2014
AbbVie Inc. S&P 500 Index NYSE Arca Pharmaceucal Index
The company also generated strong operational results during 2014. Net sales were $19.9 billion, up 7.1%
globally, excluding roughly 1.3% negative impact from foreign exchange. AbbVie also exceeded its original EPS guidance
range and raised guidance twice during 2014, which demonstrates the strength of the company’s business, management’s
performance and pipeline advancement.
Adjusted Net Sales Adjusted EPS
in millions US$ in US$
$20,000
$19,000
$18,000
2013
$18,790
$19,879
2014
$3.50
$3.00
$2.50
2013
$3.14
$3.32
2014
2015 Proxy Statement 21
EXECUTIVE COMPENSATION